Proud of my friend @rajkumar_chris presenting the game changing ORBITA-STAR trial on the main stage at #EuroPCR2024. EuroPCR’s got talent winner - well deserved against excellent competition. @rallamee @mshunshin
Michael Foley
@MikeFoley89
Cardiology Registrar | MRC Clinical Research Training Fellow | Imperial College London
331 Following 268 Followers 51 Posts
Latest posts 5
The symptom stratified analysis of ORBITA2 and the ORBITA-STAR trial both presented at #EuroPCR2024 and simultaneously published in @JACCJournals by @FloSimader and @rajkumar_chris. PCI isn’t a therapy for all symptoms, it’s a therapy for angina @rallamee @mshunshin
I’m delighted to see our paper highlighted by TCT MD. Our belief in a therapy is associated with how intuitive it seems. This may subconsciously influence the threshold we set for randomised data. We should keep this in mind as we appraise procedures, new and old. @rallamee
Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective tctmd.com/news/mechanism…View quoted post on X
Delighted to see our ORBITA-COSMIC design paper published in Eurointervention. Now for the results! My thanks as ever to my supervisors and the incredible ORBITA team @rallamee @mshunshin @rajkumar_chris @fiyyazAJ @FloSimader @drgrahamcole @ProfDFrancis
Have you already metabolized the outcomes of ORBITA 2? Next stop in the ORBITA program is called ORBITA-COSMIC. The coronary sinus Reducer (CSR) is an hourglass-shaped device which creates an artificial stenosis in the coronary sinus. The ORBITA-COSMIC trial is a randomized, placebo-controlled, double-blind trial investigating the efficacy of the CSR on quantified myocardial perfusion and stable angina. Here is the study rationale and design paper. eurointervention.pcronline.com/article/a-doub…View quoted post on X
I’m incredibly proud to have played a part in ORBITA2, presented brilliantly today by Chris Rajkumar at #AHA23. Rasha Al-Lamee has shown not only that PCI works, but so too does academic mentorship, authentic leadership and empowering her fellows. Can’t wait for the next one